|
Tumor
|
CK7
|
CK20
|
|
Hepatocellular Ca.
|
= (+ 9-17%)
|
=
|
|
Renal Cell Ca.
|
=
|
=
|
|
Prostate Ca.
|
=
|
= (0-23%+)
|
|
Neuroendocrine Ca.
|
=
|
=
|
|
Squamous Cell Ca.
|
= (+/-)
|
=
|
|
Adrenal Cortical Ca.
|
=
|
=
|
|
Gastric Adenoca. (subset)
|
=
|
=
|
Follow-up Markers for CK7=/CK20=
|
IHC Stain
|
Comment
|
|
Expression supports prostatic adenocarcinoma
|
|
|
PSAP
|
Expression supports prostatic adenocarcinoma
|
|
CEA is NOT commonly expressed in prostate adencarcinoma, renal cell carcinoma, or adrenal cortical carcinoma.
|
|
|
CK5/6
|
CK5/6 is NOT typically expressed in prostate adencarcinoma, which is in contrast to squamous cell carcinoma that usually shows expression.
|
|
Expression is commonly seen in renal cell carcinoma and adrenal cortical carcinoma.
|
|
|
Commonly expressed in renal cell carcinoma.
|
|
|
Expression commonly seen in renal cell carcinoma but not adrenal cortical carcinoma.
|
|
|
Expression supports hepatocyte origin.
|
|
|
RCC shows cytoplasmic expression, and a canalicular expression pattern is often seen in HCC.
|
|
|
Canalicular patter is common in HCC
|
|
|
HCC is negative for MOC-31. Cholangiocarcinoma (and many other carcinomas) are positive.
|
|
|
CK19
|
Expression is NOT seen in HCC.
|
|
Expression is seen in squamous cell carcinoma.
|
|
|
Inhibin
|
Expression supports adrenal cortical origin
|
|
Expression often seen in adrenal cortical carcinoma.
|
References
Arch Pathol Lab Med. Vol 134, February 2010.
Hadi, AIMM Annual Meeting, “Carcinomas of Unknown Primary”, presentation, 2011.